Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NOS1 | P29475 | 3/20 | 0.53 |
| ▸ | IL4I1 | Q96RQ9 | 1/20 | 0.50 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.48 |
| ▸ | PDE3B | Q13370 | 1/20 | 0.46 |
| ▸ | PDE3A | Q14432 | 1/20 | 0.46 |
| ▸ | OGT | O15294 | 1/20 | 0.46 |
| ▸ | HTR1A | P08908 | 2/20 | 0.46 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.46 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.46 |
| ▸ | CREBBP | Q92793 | 1/20 | 0.44 |
| ▸ | KMO | O15229 | 1/20 | 0.43 |
| ▸ | DRD2 | P14416 | 1/20 | 0.43 |
| ▸ | HTR2A | P28223 | 1/20 | 0.43 |
| ▸ | PDE10A | Q9Y233 | 1/20 | 0.43 |
| ▸ | NOS3 | P29474 | 2/20 | 0.41 |
| ▸ | NOS2 | P35228 | 2/20 | 0.41 |
| ▸ | LMNA | P02545 | 1/20 | 0.41 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.41 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1469801 | 0.87 | NOS1 (0.53) | NOS1IL4I1KDM4EALDH1A1PDE3B | |
| SCHEMBL3931441 | 0.86 | NOS1 (0.56) | NOS1IL4I1KDM4EALDH1A1PDE3B | |
| SCHEMBL5545754 | 0.83 | NOS1 (0.53) | NOS1IL4I1KDM4EALDH1A1PDE3B | |
| SCHEMBL4884404 | 0.83 | NOS1 (0.53) | NOS1IL4I1KDM4EALDH1A1PDE3B | |
| SCHEMBL17268194 | 0.82 | IL4I1 (0.56) | NOS1IL4I1KDM4EALDH1A1PDE3B | |
| SCHEMBL5535563 | 0.81 | NOS1 (0.50) | NOS1IL4I1KDM4EALDH1A1PDE3B | |
| SCHEMBL4675522 | 0.81 | KDM4E (0.52) | NOS1IL4I1KDM4EALDH1A1PDE3B | |
| SCHEMBL10392913 | 0.81 | NOS1 (0.50) | NOS1IL4I1KDM4EALDH1A1PDE3B | |
| SCHEMBL8786452 | 0.80 | NOS1 (0.49) | NOS1IL4I1KDM4EALDH1A1PDE3B | |
| SCHEMBL5536087 | 0.80 | NOS1 (0.49) | NOS1IL4I1KDM4EALDH1A1PDE3B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| JP-59112976-A | — | — | None | — | — | JP | disclosed |
| CN-107205966-B | Arylalkyl amine compounds for preventing or treating cancer | 森梅威思大学 | 2021-01-26 | — | — | CN | disclosed |
| CN-107205965-B | Arylalkyl amine compounds for preventing or treating cancer | 森梅威思大学 | 2020-10-27 | — | — | CN | disclosed |
| EP-3226851-B1 | ARYLALKYLAMINE COMPOUNDS FOR USE IN THE PREVENTION OR TREATMENT OF CANCER | SEMMELWEIS UNIV (HU) | 2020-03-18 | — | — | EP | disclosed |
| EP-3226852-B1 | ARYLALKYLAMINE COMPOUNDS FOR USE IN THE PREVENTION OR TREATMENT OF CANCER | SEMMELWEIS UNIV (HU) | 2020-03-18 | — | — | EP | disclosed |
| US-10258598-B2 | Compounds for use in the prevention or treatment of cancer | SEMMELWEIS UNIVERSITY (HU) | 2019-04-16 | — | — | US | disclosed |
| US-10258599-B2 | Compounds for use in the prevention or treatment of cancer | SEMMELWEIS UNIVERSITY (HU) | 2019-04-16 | — | — | US | disclosed |
| US-20170340582-A1 | COMPOUNDS FOR USE IN THE PREVENTION OR TREATMENT OF CANCER | FUJIMOTO CO. LTD. (JP) | 2017-11-30 | — | — | US | disclosed |
| US-20170319535-A1 | COMPOUNDS FOR USE IN THE PREVENTION OR TREATMENT OF CANCER | SEMMELWEIS UNIVERSITY (HU) | 2017-11-09 | — | — | US | disclosed |
| EP-3226852-A1 | ARYLALKYLAMINE COMPOUNDS FOR USE IN THE PREVENTION OR TREATMENT OF CANCER | Semmelweis University (HU) | 2017-10-11 | — | — | EP | disclosed |
| EP-3226851-A1 | ARYLALKYLAMINE COMPOUNDS FOR USE IN THE PREVENTION OR TREATMENT OF CANCER | Semmelweis University (HU) | 2017-10-11 | — | — | EP | disclosed |
| WO-2016088111-A1 | ARYLALKYLAMINE COMPOUNDS FOR USE IN THE PREVENTION OR TREATMENT OF CANCER | SEMMELWEIS UNIVERSITY (HU) | 2016-06-09 | — | — | WO | disclosed |
| WO-2016088112-A1 | ARYLALKYLAMINE COMPOUNDS FOR USE IN THE PREVENTION OR TREATMENT OF CANCER | SEMMELWEIS UNIVERSITY (HU) | 2016-06-09 | — | — | WO | disclosed |
| EP-0957080-B1 | NOVEL ETHYLAMINE DERIVATIVES | FUJIMOTO BROTHERS CO LTD (JP) | 2006-06-21 | — | — | EP | disclosed |
| EP-0957080-A1 | NOVEL ETHYLAMINE DERIVATIVES | Fujimoto Brothers Co., Ltd. (JP) | 1999-11-17 | — | — | EP | disclosed |
| US-5919784-A | ANXIETY, DEPRESSION | ADIR ET COMPAGNIE (FR) | 1999-07-06 | — | — | US | disclosed |
| US-5182278-A | Arterial hypotensive agents | ADIR ET COMPAGNIE (FR) | 1993-01-26 | — | — | US | disclosed |
| US-5132305-A | Analgesics | ADIR ET COMPAGNIE (FR) | 1992-07-21 | — | — | US | disclosed |
| US-4960778-A | ANALGESICS | ADIR ET CIE (FR) | 1990-10-02 | — | — | US | disclosed |
| JP-S59112976-A | SUBSTITUTED 6-(2-AMINOETHYL)-BENZOOXAZOLINONE, MANUFACTURE AND USE | RIOMU LAB U ERU EMU SA | 1984-06-29 | — | — | JP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170340582-A1 | COMPOUNDS FOR USE IN THE PREVENTION OR TREATMENT OF CANCER | TMSB10, PNMT, HNMT | NOS1 1544/4885IL4I1 2308/4885KDM4E 882/4885 |
| US-10258599-B2 | Compounds for use in the prevention or treatment of cancer | TMSB10, PNMT, HNMT | NOS1 1561/4885IL4I1 2353/4885KDM4E 869/4885 |
| US-20170319535-A1 | COMPOUNDS FOR USE IN THE PREVENTION OR TREATMENT OF CANCER | TMSB10, PNMT, HNMT | NOS1 1544/4885IL4I1 2308/4885KDM4E 882/4885 |
| US-10258598-B2 | Compounds for use in the prevention or treatment of cancer | TMSB10, PNMT, HNMT | NOS1 1561/4885IL4I1 2353/4885KDM4E 869/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.